Your browser is no longer supported. Please, upgrade your browser.
ORMP Oramed Pharmaceuticals Inc. weekly Stock Chart
Oramed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own13.07% Shs Outstand23.22M Perf Week-4.30%
Market Cap60.50M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float20.30M Perf Month-23.93%
Income-10.80M PEG- EPS next Q-0.19 Inst Own12.60% Short Float0.95% Perf Quarter-23.50%
Sales2.70M P/S22.41 EPS this Y3.80% Inst Trans5.58% Short Ratio1.42 Perf Half Y-10.40%
Book/sh1.47 P/B1.82 EPS next Y-21.10% ROA-30.40% Target Price- Perf Year-13.87%
Cash/sh1.80 P/C1.48 EPS next 5Y- ROE-49.80% 52W Range2.32 - 6.05 Perf YTD-48.16%
Dividend- P/FCF- EPS past 5Y-5.90% ROI-77.00% 52W High-57.44% Beta1.56
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low11.14% ATR0.25
Employees13 Current Ratio10.00 Sales Q/Q0.00% Oper. Margin- RSI (14)35.08 Volatility11.17% 8.58%
OptionableYes Debt/Eq0.00 EPS Q/Q57.80% Profit Margin- Rel Volume2.06 Prev Close2.67
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume135.68K Price2.58
Recom1.70 SMA20-14.39% SMA50-26.26% SMA200-33.06% Volume263,463 Change-3.56%
Mar-11-20Initiated Aegis Capital Buy $5.50
Sep-11-19Initiated Ladenburg Thalmann Buy $7
Dec-11-17Resumed B. Riley FBR, Inc. Buy $20
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Nov-19-15Initiated FBR Capital Outperform $15
Apr-13-15Resumed MLV & Co Buy $27 → $30
Jan-30-14Reiterated Aegis Capital Buy $30 → $35
Jan-08-14Reiterated Aegis Capital Buy $25 → $30
Jan-08-14Initiated MLV & Co Buy $27
Dec-03-13Initiated Aegis Capital Buy $25
Sep-22-20 07:12AM  
Sep-21-20 08:25AM  
Sep-15-20 08:25AM  
Sep-03-20 08:10AM  
Aug-11-20 12:20PM  
Jul-16-20 10:19AM  
Jul-15-20 08:55AM  
Jul-08-20 06:09PM  
Jun-19-20 05:34AM  
Jun-15-20 08:25AM  
Jun-09-20 07:03AM  
Jun-04-20 06:59PM  
May-05-20 09:22AM  
Apr-14-20 07:10AM  
Apr-07-20 07:40AM  
Apr-01-20 08:40AM  
Mar-30-20 09:01AM  
Mar-19-20 08:40AM  
Mar-11-20 06:30AM  
Feb-27-20 09:15AM  
Feb-26-20 04:05PM  
Feb-12-20 09:42AM  
Feb-04-20 08:25AM  
Jan-30-20 07:25AM  
Jan-28-20 07:25AM  
Jan-23-20 08:00AM  
Jan-21-20 07:25AM  
Jan-09-20 07:00AM  
Jan-07-20 11:38AM  
Dec-22-19 06:17PM  
Dec-05-19 09:12AM  
Dec-02-19 09:16AM  
Nov-25-19 09:57AM  
Nov-21-19 08:27AM  
Nov-19-19 08:55AM  
Nov-14-19 07:28AM  
Nov-12-19 07:00AM  
Oct-21-19 03:06PM  
Sep-20-19 12:20PM  
Sep-18-19 08:38AM  
Sep-17-19 08:40AM  
Sep-03-19 08:25AM  
Aug-16-19 08:31AM  
Aug-05-19 04:05PM  
Jul-11-19 12:28PM  
Jul-10-19 08:40AM  
Jul-02-19 08:25AM  
Jun-25-19 10:50AM  
Jun-18-19 08:40AM  
Jun-03-19 09:25AM  
May-21-19 08:55AM  
May-07-19 04:15PM  
Apr-29-19 08:25AM  
Apr-28-19 09:47AM  
Apr-11-19 08:55AM  
Apr-04-19 08:55AM  
Apr-03-19 08:55AM  
Mar-28-19 08:40AM  
Mar-26-19 08:40AM  
Feb-06-19 02:31PM  
Jan-24-19 10:45AM  
Jan-22-19 08:25AM  
Jan-15-19 08:55AM  
Jan-09-19 08:40AM  
Dec-17-18 01:45PM  
Nov-27-18 01:12PM  
Nov-15-18 11:45AM  
Nov-13-18 08:48AM  
Nov-05-18 08:25AM  
Oct-23-18 08:25AM  
Oct-04-18 08:25AM  
Sep-20-18 02:23PM  
Sep-17-18 10:35AM  
Aug-28-18 08:25AM  
Jul-24-18 08:25AM  
Jul-17-18 08:37AM  
Jul-12-18 06:36PM  
Jul-06-18 05:00PM  
Jul-03-18 01:48AM  
Jun-25-18 08:25AM  
Jun-21-18 08:25AM  
Jun-19-18 08:25AM  
Jun-12-18 08:25AM  
May-30-18 08:25AM  
May-10-18 09:39AM  
May-07-18 08:25AM  
Apr-23-18 08:25AM  
Mar-27-18 08:25AM  
Mar-15-18 08:48AM  
Feb-28-18 08:25AM  
Feb-20-18 08:25AM  
Feb-06-18 08:25AM  
Jan-19-18 10:50AM  
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, which completed phase II clinical trials is an orally ingestible insulin capsule for the treatment of diabetes; and ORMD-0901 that completed phase I clinical trials is an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.